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Abstract
Purpose: Anastomotic complications following lung transplantation (LuTx) have been described in up to 15% of patients. Challenging to treat,
they are associated with high morbidity and a mortality rate of 2—5%. The aim of this study was to analyze the incidence of complications in a
consecutive series of bronchial anastomosis after LuTx at our center and to delineate the potential risk factors.Methods: Between 1992 and 2007,
441 bronchial anastomoses were performed in 235 patients. Indications for transplantation were cystic fibrosis (35.7%) emphysema (28.1%)
pulmonary fibrosis (12.8%) and pulmonary hypertension (7.7%). There were 206 sequential bilateral and 28 single transplants including lobar
engraftments in 20 cases. The donor bronchus was shortened to the plane of the lobar carina including the medial wall of the intermediate
bronchus. Peribronchial tissue was left untouched. Anastomosis was carried out using a continuous absorbable running suture (PDS 4/0) at the
membranous and interrupted sutures at the cartilaginous part. Six elective surveillance bronchoscopies were done monthly during the first half-
year post-LuTx, with detailed assessment of the pre- and post-anastomotic airways. Results: One-year survival since 2000 was 90.5%. In all 441
anastomoses performed, no significant dehiscence was observed. In one patient, a small fistula was detected and closed surgically on
postoperative day five. Fungal membranes were found in 50% of the anastomoses at 1 month and in 14% at 6 months. Discrete narrowing of
the anastomotic lumen without need for intervention was found in 4.9% of patients at 1 month and in 2.4% at 6 months. Age, cytomegalovirus
status, induction therapy, immunosuppressive regimen, ischemic time, and ventilation time had no influence on bronchial healing. Conclusions:
Clinically relevant bronchial anastomotic complications after LuTx can be avoided by use of a simple standardized surgical technique. Aggressive
antibiotic and antifungal therapy might play an important supportive role.
# 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Themajor cause of death following pulmonary transplanta-
tion in the first 15 years after the first human lung
transplantation was airway dehiscence, representing a for-
midableobstacle towidespreaduseofthisnovelprocedure [1].
Pulmonary transplantation is unique among all solid organ
transplantations, since systemic arterial blood supply is not
(routinely) restored during engraftment. For this reason,
anastomotic complications have primarily been attributed to
ischemia of the donor bronchus [2]. Additionally rejection
[3], intense immunosuppressive therapy [4], invasive infec-
tions [5], or inadequate organ preservation [2] were factors§ Presented at the 16th European Conference on General Thoracic Surgery,
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healing. Furthermore, severe reperfusion edema and early
rejection episodes have been shown as independent
predictors of bronchial complications [6].
Recently, refinements in lung preservation and surgical
technique, improvements in patient selection, postoperative
care and immunosuppression have reduced the prevalence of
airway complications [7]. Reflecting these changes, the
contemporary rate of anastomotic lesions following LuTx has
dropped from 80% before 1983 [15] to 2.6—23.8% [6—14].
In this investigation we analyzed the incidence of airway
anastomotic complications in 235 consecutive patients at our
center to delineate potential risk factors.2. Patients and methods
We reviewed the data from a consecutive series of 235
patients transplanted at our center between November 1992Surgery. Published by Elsevier B.V. All rights reserved.
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(9—69), comprising121 femalesand114males. The indications
for lung transplantation were: cystic fibrosis (n = 84),
emphysema (n = 66), pulmonary fibrosis (n = 30), pulmonary
hypertension (n = 18) and others (n = 37) (Table 1).
This series consisted of one heart—lung, 28 single lung and
206 bilateral sequential lung transplants for a total of 441
anastomoses performed using the same technique. Of this
cohort 28 patients died in the hospital (in-hospital mortality
11%) and one heart—lung transplant patient was excluded
from the study leaving 206 patients available for the analysis.
A total of 391 anastomoses at risk in 206 patients were
evaluated using elective bronchoscopy during the first 6Table 1
Recipient variables (441 anastomoses in 235 patients).
Age (years) 41.8 (9—69)
Weight (kg) 58 (24—122)
Height (cm) 166.8 (133—191)
Gender
Male 114 (48.5)
Female 121 (51.5)
Diagnosis
Emphysema 66 (28.1)
Cystic fibrosis 84 (35.7)
IPF 30 (12.8)
PPH 18 (7.7)
Other 37 (15.7)
Preoperative steroid use
Yes 51 (21.7)
CMV status (recipient/donor)
neg/neg 86 (36.6)
neg/pos 56 (23.8)
pos/neg 36 (15.3)
pos/pos 57 (24.3)
Induction
Basiliximab 132 (56.2)
ATG 13 (8.4)
Immunosuppression
C-Az-P 62 (26.4)
C-MMF-P 173 (73.6)
Organ preservation solution
Euro-Collins 91 (38.8)
Perfadex 144 (61.2)
Type of operation
Unilateral transplantation 28 (11.9)
Bilateral transplantation 206 (87.8)
Heart—lung transplantation 1 (0.4)
Down-sizing
Yes 65 (27.7)
Lobar transplantation 20 (8.5)
CRP at transplantation 18 (1—162)
Total operation time (min) 382.6 (140—970)
Ischemia time (min)
Right lung 234.3 (62—658)
Left lung 304.7 (79—533)
Ventilation time (days) 4.8 (1—218)
ICU time (days) 11.5 (1—218)
Mortality (in-hospital) 28 (11.9)
Values are given as n (%) or mean (minimum—maximum). CRP: C reactive
protein (mg/l). IPF: interstitial pulmonary fibrosis, PPH: primary pulmonary
hypertension, neg: negative, pos: positive, ATG: anti-thymocyte globulin, C-
Az-P: cyclosporine—azathioprine—prednisone, C-MMF-P: cyclosporine—myco-
phenolate mofetil—prednisone, ICU: Intensive care unit.postoperative months. Since 2000 1-year and 5-year survival
was 90.5% and 78%, respectively.
Euro-Collins solution was used until 2000; thereafter
Perfadex (Vitrolife, Sweden) had been introduced. Before
antegrade flush 500 mg prostaglandin E1 (Prostin VR, Upjohn,
Puurs, Belgium) was injected into the pulmonary artery in all
cases. We are also using retrograde flush with Perfadex at the
time of the back-table preparation since 2000.
The surgical approach for single lung transplantation was
an anterolateral thoracotomy. For bilateral sequential lung
transplantation bilateral trans-sternal anterior thoracotomy
(clamshell incision) or, since 2000, two separate anterolat-
eral thoracotomies were performed.
First the bronchial anastomoses were carried out. The
recipient’smain bronchuswas divided one ring proximal of the
branching of the upper lobe bronchus. The bronchial arteries
were ligated, avoiding electrocoagulation of the peribronchial
tissue. All dissection close to the bronchus was done using
‘minimal’ or ‘no touch’ technique in order to keep the
peribronchial tissue intact. The donor bronchus was cut back
as close to the origin of the upper lobe bronchus as possible,
with special attention to keep the peribronchial tissues
undisturbed (Fig. 1). We consider the oblique resection of the
medial (extrapulmonary) wall of the intermediate bronchus
important. Absorbable suture material polydioxanone (PDS,
Ethicon Inc., NJ) was used. A continuous suture of the
membranous wall (PDS, 4/0) and end-to-end anastomosis with
interrupted single sutures (PDS, 3/0) of the cartilaginous part
wasperformed. Thefirst suture to unite the cartilaginousparts
was placed in the middle of the circumference to achieve
optimal size matching. Forced telescoping of the anastomosis
was avoided, and telescoping was employed only when it
occurred spontaneously in the event of donor-to-recipient size
mismatch. Only in the first three recipients of this series was
the anastomosis covered with omentum. Thereafter, this
technique was abandoned and peribronchial tissue was used.Fig. 1. Cut points on the donor bronchus. (a) The donor bronchus should be cut
back as close as possible to the upper lobe bronchus origin in an oblique plane
with special attention to keep peribronchial tissues undisturbed (b) If donor
bronchus cut at this level there will be a risk zone for bronchial ischemia (gray
zone).
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therapy with cyclosporine, azathioprine (since 1997 replaced
by mycophenolate mofetil), prednisone and prophylaxis
against pneumocystis carinii, cytomegalovirus (CMV) and
fungal infections. The initial dose of methylprednisone was
1000 mg (500 mg/completed anastomosis) i.v. before reper-
fusion followed by 125 mg i.v. for the first postoperative day.
Then the recipients received 0.5 mg/kg/day prednisone as a
maintenance dose.
Antibiotic therapy was adjusted based on the antibiotic
sensitivities from preoperative sampling of the recipient and
the donor bronchus before implantation.
Airway status was examined with flexible bronchoscopy
after completion of anastomosis during the operation. Follow-
up bronchoscopies together with transbronchial surveillance
biopsy were done every 3—4 weeks for the first 6 months.
Bronchial healing was assessed according to the classifica-
tion of Couraud as follows: grade 1: complete primarymucosal
healing; grade 2a: complete primary healing without necrosis,
partial primary mucosal healing; grade 2b: complete primary
healing without necrosis, no primary mucosal healing; grade
3a: limited focal necrosis (extending less than 5 mm from the
anastomotic line); grade 3b: extensive necrosis [16].
Furthermore, bronchoscopic descriptions were also eval-
uated according to presence and extent of fungal mem-
branes, hyperemia, and hyperplasia using a semi quantitative
scale as follows: 0: none; 1: mild; and 2: severe. Luminal
narrowing was defined as 10-30 luminal occlusion relative to
proximal, pre-anastomotic native bronchus.
We compared the patients displaying luminal narrowing to
recipients without during the first surveillance bronchoscopy.
The variables assessed were age, weight, height, gender,Table 2
Bronchoscopy details in 391 anastomoses at risk.
Bronchoscopy 1 2 3
Day (mean) 39.1 72.1 106.2
CRP (mean) 11.2 4.1 4.8
Fungal membrane (L; R, %)
None 50.5; 48 48.1; 44.7 65.4; 6
Mild 35; 35.9 43.1; 44.1 26.8; 3
Severe 14.5; 16.1 8.8; 11.2 7.8; 7.
Hyperemia (L; R, %)
None 31.7; 33.5 30.6; 31.6 44.4; 4
Mild 47.8; 45.7 54.4; 51.3 45.1; 4
Severe 20.6; 20.8 15; 17.1 10.5; 1
Hyperplasia (L; R,%)
None 80.2; 79.2 83.9; 86.8 86.3; 8
Mild 17.6; 18.5 14.3; 10.6 12.4; 1
Severe 2.2; 2.3 1.9; 2.6 1.3; 2.
Luminal narrowing (%)
No 95.1 95.1 95.6
Left 1 1.9 1.0
Right 0.5 1.5 1.0
Bilateral 3.4 1.5 2.4
Couraud classification (%)
1 73.3 83.9 88.3
2a 20.4 10.6 7.2
2b 5.8 4.8 3.5
3a 0.5 0.5 1.0
L: left, R: right. Bronchoscopies are evaluated using a semi quantitative scale for fung
severe. CRP: C reactive protein (mg/l).indication for transplantation, preoperative steroid use,
cytomegalovirus status, induction therapy, immunosuppres-
sion, preservation solution, type of operation, down-sizing, C
reactive protein (CRP) at transplantation, total operation
time, ischemia time, duration of ventilation and ICU stay.3. Statistical analysis
All data were collected retrospectively. The statistical
analysis was performed with SPSS 15.0 for Windows. To test
for univariate differences in categorical variables, we used
Pearson’s chi-square test. For continuous variables, we used
the Mann—Whitney U test. We considered p < 0.05 to
indicate statistical significance.4. Results
In this study, a total of 391 anastomoses at risk were
evaluated. Altogether, no severe airway complications
occurred, except for one patient who experienced a small
anastomotic fistula directly postoperatively, which was
closed surgically at day five following transplantation. In
the first surveillance bronchoscopy luminal narrowing was
observed in 10 patients (4.9%) (18/391 anastomoses, 4.6%).
Yet, there was no clinical meaningful respiratory impair-
ment, with no need for stenting or surgical revision. The rate
of luminal narrowing decreased to 2.4% (5/206 patients) (9/
391 anastomoses, 2.3%) at the sixth bronchoscopy (Table 2).
Complete primary mucosal healing based on the Couraud
classification was seen in 73.3% of the anastomoses (Couraud4 5 6
133.2 170.3 202.5
3.9 3.1 5.6
0 68.3; 63.9 72.7; 70.2 85.4; 86.4
2.4 28.9; 32.3 22.7; 27.3 14.1; 13.1
6 2.8; 3.8 4.7; 2.5 0.5; 0.5
0.7 53.5; 50 57; 56.2 50.8; 55.4
8.3 39.4; 43.2 37.5; 38.8 43.2; 37.5
1 7; 6.8 5.5; 5 5.9; 7.1
3.6 86.5; 86.5 92.2; 90.1 91.5; 92.9
4.4 10.6; 11.3 6.3; 9.9 7.6; 6.3
1 6.8; 2.3 1.6; 0 0.8; 0.9
96.6 96.1 97.6
1.0 1.4 0.5
0.5 0.5 0
1.9 1.9 1.9
94.2 93.7 95.2
4.8 5.3 3.8
1.0 0.5 1.0
0 0.5 0
al membranes, hyperemia, and hyperplasia as follows: 0: none; 1: mild; and 2:
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Table 3
Comparison of variables between the groups with and without luminal narrow-
ing.
Group I (n = 196) Group II (n = 10) p value
Age (years) 42.2 (12—69) 43.8 (18—60) 0.79
Weight (kg) 57.2 ((24—103) 56.4 (40—75) 0.76
Height (cm) 166.8 (133—191) 167.7 (153—182) 0.85
Gender (n) 0.97
Male 98 5
Female 98 5
Diagnosis 0.35
Emphysema 60 (30.6) 2 (20)
Cystic fibrosis 73 (37.2) 3 (30)
IPF 22 (11.2) 2 (20)
PPH 11 (5.6) —
Other 30 (15.3) 3 (30)
Preoperative steroid use 0.15
Yes 42 (21.4) 4 (40)
CMV status (recipient/donor) 0.94
neg/neg 69 (35.2) 4 (40)
neg/pos 53 (27) 2 (20)
pos/neg 28 (14.3) 2 (20)
pos/pos 47 (23.9) 2 (20)
Induction
Basiliximab 111 (56.6) 7 (70) 0.24
ATG 13 (13.5) — 0.40
Immunosuppression 0.63
C-Az-P 47(23.9) 1 (10)
C-MMF-P 149 (76.1) 9 (90)
Organ preservation solution
Euro-Collins 78 (39.7) 7 (70) 0.04
Perfadex 118 (60.3) 3 (30)grade 1) at first bronchoscopy, which increased to 95.2% by
the end of the 6-month timeframe. Primary healing,
however, displaying partial mucosal healing without necrosis
(Couraud grade 2a and/or 2b) was seen in 26.2% of the
anastomoses at the first bronchoscopy, which decreased to
4.8% at the sixth bronchoscopy, never requiring any
treatment (Table 2).
Severe fungal membranes were found in 14.5% (left
bronchus) and in 16.1% (right bronchus) of the anastomoses
during the first surveillance inspection (Table 2). This was
reduced to 0.5% at the sixth bronchoscopy. As a matter of
fact, by 6 months, about 85% of the anastomoses were free of
fungal membranes (Table 2).
There were 10 patients with luminal narrowing compared
to 196 patients without. Age, weight, height, gender,
diagnosis leading to transplantation, preoperative steroid
use, CMV status, induction therapy, immunosuppression,
type of operation, down-sizing, CRP at transplantation, total
operation time, ischemia time, time on ventilator and ICU
duration did not differ between the two groups (Table 3).
Only type of organ preservation solution ( p = 0.04) and lobar
transplantation ( p = 0.02) differed significantly between
groups.
When we compared the first and the sixth bronchoscopies
only the extent of hyperplasia, and the Couraud grading
differed significantly between the two groups (for the first
bronchoscopy; p = 0.0001, p = 0.002, respectively; for the
sixth bronchoscopy p = 0.0001 and p = 0.01, respectively).
Presence and extent of fungal membranes and hyperemia
were comparable between the two time points.Type of operation 0.33
Unilateral transplantation 19 (9.7) 2 (20)
Bilateral transplantation 177 (90.3) 8 (80)
Down-sizing
Yes 56 (28.5) 2 (20)
Lobar transplantation 17 (8.6) 1 (10) 0.02
CRP at transplantation 17.2(1—138) 18.4(1—58) 0.69
Total operation time (min) 379 (140—620) 335 (205—435) 0.30
Ischemia time (min)
Right lung 232 (65—475) 237.3 (162—335) 0.70
Left lung 306 (111—533) 269 (79—379) 0.38
Ventilation time (day) 2.7 (1—75) 1.2 (1—3) 0.23
ICU time (day) 9.04 (1—142) 10.5 (2—29) 0.44
Values are given as n (%) or mean (minimum—maximum). Group I: patients
without luminal narrowing at the first bronchoscopy, group II: patients with
luminal narrowing at the first bronchoscopy. CRP: C reactive protein (mg/l).
IPF: interstitial pulmonary fibrosis, PPH: primary pulmonary hypertension,
neg: negative, pos: positive, ATG: anti-thymocyte globulin, C-Az-P: cyclos-
porine—azathioprine—prednisone, C-MMF-P: cyclosporine—mycophenolate
mofetil—prednisone, ICU: Intensive care unit.5. Discussion
In all 441 anastomoses performed, no significant dehis-
cence was observed. In one patient, a small fistula was
detected and closed surgically on postoperative day five. In
only 4.9% (10/206) of recipients luminal narrowing was found
at the first surveillance bronchoscopy in a consecutive series
of 391 bronchial anastomoses (4.6%, 18/391). This rate
decreased to 2.3% (9/391) after 6 months. None of these
patients required any intervention, and there was no death
related to bronchial anastomotic complications.
Bronchial ischemia is reported to be a significant risk
factor for the development of airway complications [9]. The
viability of the donor bronchus is initially dependent upon
retrograde low-pressure collaterals derived from the pul-
monary artery as bronchial arterial circulation is lost during
the harvest of the donor lungs [3]. Several techniques have
been proposed to protect the bronchial anastomosis: keeping
the donor bronchus as short as possible and wrapping the
anastomosis with vascularized pedicles [2], direct revascu-
larization of donor bronchial arteries [17], and double
antegrade and retrograde flush perfusion of the donor lungs
at the time of harvest [18].
Based on the favorable results from animal studies,
routine use of bronchial anastomotic omentopexy (omen-
tum wrapping) in the early days of lung transplantation was
thought to be a key strategy to overcome bronchial healing
problems by enhancing the microcirculation of the donor
bronchus [7]. This technique, although widely used then,has been shown to be no longer essential [19]. We, like
other transplant centers, also used omentopexy initially,
but then abandoned this method. Another strategy aimed at
avoiding perioperative steroids as they were believed to
negatively influence the healing process. However, pre-
vention of rejection and potential amelioration of reperfu-
sion injury are useful effects of steroids [20]. During acute
rejection episodes, microcirculation may be significantly
impaired due to an increase in pulmonary vascular
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supply [21].
Combined parenteral administration of heparin and
prostaglandin early in the postoperative period has been
advocated in order to increase microcirculation and retro-
grade perfusion to the donor bronchus [19]. In our series all
donor lungs were preserved with prostaglandin E1 injected
into the main pulmonary artery before starting with cold
antegrade perfusion of pulmonary preservation solution.
Heparin is started 6 h postoperatively with 5000 IU/24 h and
increased gradually to 10,000 and further to 15,000 IU/24 h
continuous i.v. infusion depending on the clinical picture. We
do not employ prostaglandins in the postoperative period.
Recently, severe reperfusion injury and early rejection
episodes have been demonstrated to be independent
predictors of bronchial complications [6]. We and other
investigators have demonstrated that the number of acute
rejection episodes was not related to the occurrence of
bronchial complications [7,9,22].
A strong correlation between the intrabronchial presence
of Aspergillus and the incidence of airway complications has
been reported [11]. When bronchial necrosis was described
at the first postoperative bronchoscopy together with
Aspergillus infection, the incidence of later airway compli-
cations was higher than if there was necrosis alone. In our
protocol we start with antifungal therapy early postopera-
tively using nebulized amphotericin B (2  10 mg/day) and
per oral itraconazole (2  200 mg/day). Our findings support
this approach as nearly 85% of the patients did not have
fungal membranes at their 6th bronchoscopy. In addition the
rate of severe fungal membranes decreased from 15% to
0.5%. This, in part, may explain the low incidence of airway
complications in the present series.
We firmly believe that the surgical technique is paramount
for the future successful healing of the bronchial anasto-
mosis. The surgical approach for performing the anastomosis
may vary among transplant centers. Telescoping, end-to-end
anastomosis with a running suture for the membranous part
and interrupted sutures for the cartilaginous part, and end-
to-end anastomosis with a single running suture are most
often used [7,9,12,22]. Some centers have reported changing
their anastomotic technique from telescoping to end-to-end
single suture, due to a high airway complication rate [12,13].
Others have employed telescoping or a modified telescoping
technique from the beginning of their program with a low
complication rate [8,9]. In fact, in most of the studies
telescoping has been demonstrated to be an independent risk
factor for airway complication [7,13,14]. We have not
modified our technique since our program was established
in 1992. Furthermore, we think that resection of the donor
bronchus down to the lobar carina in an oblique plane
(Fig. 1), in conjunction with keeping the peribronchial tissue
intact is a critical step while performing the bronchial
anastomosis.
The often cited disadvantages for a single-stitch-techni-
que compared to a running suture, more time required, a
higher load of foreign tissue due to the necessity to tie
multiple knots and an overall increased tissue irritation, do
not reflect our experience.
There is no standardized internationally accepted classi-
fication scheme to assess airway healing [11,12,16]. Couraudet al. [16] graded airway healing based on the bronchoscopic
appearance, showing a good correlation with the subsequent
development of anastomotic sequel. This grading system
ranges from perfect mucosal healing (grade 1) to extensive
necrosis (grade 3b). In their report the incidence of
anastomotic complications significantly differed between
grades 3a and 3b compared to grades 1, 2a and 2b. We also
used Couraud classification to assess airway healing in our
series. In the first bronchoscopy we detected a significant
difference between the groups without luminal narrowing
andwith luminal narrowing. This observation is in accordance
with the original report demonstrating high incidence of
airway complications in grades 3a and 3b compared to grades
1, 2a and 2b [16].
In conclusion, our data demonstrate that bronchial
anastomotic complications can be avoided by use of a
standardized surgical technique, which respects the fact that
the donor bronchus is poorly vascularized. Prevention of
fungal infections with aggressive antifungal treatment may
play an important additive role.
References
[1] Veith FJ, Kamholz SL, Mollenkopf FP, Montefusco CM. Lung transplanta-
tion. Transplantation 1983;35:271—8.
[2] Shennib H, Massard G. Airway complications in lung transplantation. Ann
Thorac Surg 1994;57:506—11.
[3] Takao M, Katayama Y, Onoda K, Tanabe H, Hiraiwa T, Mizutani T, Yada I,
Namikawa S, Yuasa H, Kusaqawa M. Significance of bronchial mucosal
blood flow for the monitoring of acute rejection in lung transplantation. J
Heart Lung Transplant 1991;10:956—67.
[4] Lima O, Cooper JD, Peters WJ, Ayabe H, Townsend E, Luk SC, Goldberg M.
Effects of methylprednisolone and azathioprine on bronchial healing
following lung autotransplantation. J Thorac Cardiovasc Surg 1981;82:
211—5.
[5] Kshettry VR, Kroshus TJ, Hertz MI, Hunter DW, Shumway SJ, Bolman IIIRM.
Early and late complications after lung transplantation: incidence and
management. Ann Thorac Surg 1997;63:1576—83.
[6] Ruttmann E, Ulmer H, Marchese M, Dunst K, Geltner C, Margreiter R,
Laufer G, Mueller LC. Evaluation of factors damaging the bronchial wall
in lung transplantation. J Heart Lung Transplant 2005;24(March (3)):
275—81.
[7] Date H, Trulock EP, Arcidi JM, Sundaresan S, Cooper JD, Patterson GA.
Improved airway healing after lung transplantation. An analysis of 348
bronchial anastomoses. J Thorac Cardiovasc Surg 1995;110(November
(5)):1424—32.
[8] Schroder C, Scholl F, Daon E, Goodwin A, Frist WH, Roberts JR, Christian
KG, Ninan M, Milstone AP, Loyd JE, Merrill WH, Pierson III RN. A modified
bronchial anastomosis technique for lung transplantation. Ann Thorac
Surg 2003;75(June (6)):1697—704.
[9] Alvarez A, Algar J, Santos F, Lama R, Aranda JL, Baamonde C, Lopez-Pujol
J, Salvatierra A. Airway complications after lung transplantation: a
review of 151 anastomoses. Eur J Cardiothorac Surg 2001;19(April
(4)):381—7.
[10] Choong CK, Sweet SC, Zoole JB, Guthrie TJ, Mendeloff EN, Haddad FJ,
Schuler P, De la Morena M, Huddleston CB. Bronchial airway anastomotic
complications after pediatric lung transplantation: incidence, cause,
management, and outcome. J Thorac Cardiovasc Surg 2006;131(January
(1)):198—203.
[11] Herrera JM, McNeil KD, Higgins RS, Coulden RA, Flower CD, Nashef SA,
Wallwork J. Airway complications after lung transplantation: treatment
and long-term outcome. Ann Thorac Surg 2001;71(March (3)):989—93.
discussion 993—4.
[12] Aigner C, Jaksch P, Seebacher G, Neuhauser P, Marta G, Wisser W,
Klepetko W. Single running suture—the new standard technique for
bronchial anastomoses in lung transplantation. Eur J Cardiothorac Surg
2003;23(April (4)):488—93.
[13] Murthy SC, Blackstone EH, Gildea TR, Gonzalez-Stawinski GV, Feng J,
Budev M, Mason DP, Pettersson GB, Mehta AC. Impact of anastomotic
W. Weder et al. / European Journal of Cardio-thoracic Surgery 35 (2009) 293—298298airway complications after lung transplantation. Ann Thorac Surg
2007;84(August (2)):401—9.
[14] Van De Wauwer C, Van Raemdonck D, Verleden GM, Dupont L, De Leyn P,
Coosemans W, Nafteux P, Lerut T. Risk factors for airway complications
within the first year after lung transplantation. Eur J Cardiothorac Surg
2007;31(April (4)):703—11.
[15] Wildevuur CRH, Benfield JR. A review of 23 human lung transplants by 20
surgeons. Ann Thorac Surg 1970;9:489—515.
[16] Couraud L, Nashef SA, Nicolini P, Jougon J. Classification of airway
anastomotic healing. Eur J Cardiothorac Surg 1992;6:496—7.
[17] Baudet EM, Dromer C, Dubrez J, Jougon JB, Roques X, Velly J-F, Deville C,
Couraud L. Intermediate-term results after en bloc double-lung trans-
plantation with bronchial arterial revascularization. J Thorac Cardiovasc
Surg 1996;112:1292—300.
[18] Alvarez A, Salvatierra A, Lama R, Algar J, Cerezo F, Santos F, Baamonde C,
Pujol JL. Preservation with a retrograde second flushing of Eurocollins in
clinical lung transplantation. Transplant Proc 1999;31:1088—90.
[19] Shafers HJ, Haverich A, Wagner TO, Wahlers T, Alken A, Borst HG.
Decreased incidence of bronchial complications following lung transplan-
tation. Eur J Cardiothorac Surg 1992;6:174—9.
[20] Novick RJ, Menkis AH, McKenzie FN, Reid KR, Pflugfelder PW, Kostuk WJ,
Ahmad D. The safety of low dose prednisone before and immediately
after heart—lung transplantation. Ann Thorac Surg 1991;51:642—5.
[21] Calhoon JH, Grover FL, Gibbons WJ, Bryan CL, Levine SM, Bailey SR,
Nichols L, Lum C, Trinkle JK. Single lung transplantation. Alternative
indications and technique. J Thorac Cardiovasc Surg 1991;101:816.
[22] Schmid RA, Boehler A, Speich R, Frey HR, Russi EW, Weder W. Bronchial
anastomotic complications following lung transplantation: still a major
cause of morbidity? Eur Respir J 1997;10(December (12)):2872—5.
Appendix A. Conference discussion
Dr D. Van Raemdonck (Leuven, Belgium): I may have missed it, but I did
not see any slide on the indications for lung transplantation in your center.
Our group reported our bronchial complications at this meeting two years
ago in Stockholm (Van De Wauwer C et al. Eur J Cardiothorac Surg
2007;31:703—710) and we found that especially in tall emphysemarecipients we had more bronchial complications than in other patients,
and this has also been reported by other groups. Can you tell us how many
emphysema patients you transplanted and whether this could have
influenced your good results?
Dr Inci: In our center themost common indication is cystic fibrosis followed
by COPD. So about 27% of our patients have chronic obstructive pulmonary
diseases, including alpha-1 antitrypsin deficiency. This was on the slide, but I
didn’t write the numbers, I mentioned just as a percentage, as a second
highest percentage. I also evaluated in univariate analysis the height of the
recipients also, but this was not significant.
Dr G.A. Patterson (St. Louis, MO): Can I ask a technical question. I have an
idea that a significant explanation for the low risk of ischemia is how very short
you make the donor airway, particularly on the right, and if that donor airway
division extends into the bronchus intermedius, it seems to me that the hilum
of the right lung is going to have to be elevated significantly. Having the donor
lung so high, does that in any way complicate either the arterial or the venous
anastomosis?
Dr Inci: We cut obliquely up to the upper lobe, but we do not shorten the
intermediate bronchus too much. In an oblique plane, we leave the
membranous part may be a little bit longer than shown in the slide. And so
after the anastomosis, we do not see any problem with the arterial or venous
anastomosis.
Dr H. Kara (Istanbul, Turkey): My question is about the application of
steroids to the donor. Do you believe that giving steroids to the donor would
affect the success of the stump after transplantation?
Dr Inci: During the early days of transplantation, this issue was a little bit of
concern. When you check the papers published they wanted to avoid giving
steroids to the donors in order to have a good healing in the airways, and then
after data from St. Louis and other centers, they saw that it does not have a
negative effect on healing, plus they are given steroids for prevention of
rejection and ischemia-reperfusion injury. In addition when you have an
ischemia-reperfusion injury you have a construction of the collaterals on the
bronchus so you have low perfusion, and you need these collaterals in order for
the healing of the anastomosis. We now allow the patients with steroids, and
donor steroids also, and perioperatively we give 500 mg to each side after we
finish the anastomosis. So 1000 mg methylprednisolone for each patient, and
then we continue with the steroids.
